Talk Bio

Celltrion presented interim preclinical results for CT-P72 / ABP-102, a HER2-targeting T‑cell engager multispecific antibody, showing strong anticancer effects against HER2 high-expression tumors while sparing HER2‑low cells. In primate studies CT-P72 / ABP‑102 was well tolerated at up to 80 mg/kg; it also demonstrated superior activity in gastric cancer models resistant to existing HER2 therapies and showed activity in bladder, biliary tract, and breast cancers. The FDA cleared a Phase 1 clinical trial for CT‑P72 / ABP‑102 in HER2‑positive solid tumors; Celltrion is now in patient‑screening and plans to pursue FDA fast track designation this year. Sources: Celltrion Confirms Efficacy of Next-Generation Multispecific Antibody ... THE BIO (더바이오)'s Post - LinkedIn Celltrion shifts to new drug development and starts U.S. ... Abpro and Celltrion, Inc. Announce U.S. FDA IND Clearance Celltrion Announces Results of Preclinical Studies of Two New ADC ... Korea's top ...